Suppr超能文献

p62/sequestosome 1 在人结直肠癌中作为与细胞增殖相关的一种强有力的预后预测因子。

p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation.

机构信息

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Department of Pathology, Tohoku University Hospital, Sendai, Japan.

出版信息

Cancer Med. 2017 Jun;6(6):1264-1274. doi: 10.1002/cam4.1093. Epub 2017 May 23.

Abstract

p62/sequestosome 1 (p62) is a multi-domain protein that functions as a receptor for ubiquitinated targets in the selective autophagy and serves as a scaffold in various signaling cascades. p62 have been reported to be up-regulated in several human malignancies, but the biological roles and significance of p62 are still poorly understood in colorectal carcinoma. We immunohistochemically evaluated p62 in 118 colorectal adenocarcinoma and 28 colorectal adenoma cases. We used four colon carcinoma cells (HCT8, HT29, COLO320, and SW480) in the in vitro studies. p62 immunoreactivity was detected in 11% of colorectal adenoma cases and 31% of adenocarcinoma cases, while it was negligible in the normal epithelium. The immunohistochemical p62 status was significantly associated with synchronous liver metastasis, and it turned out to be an independent adverse prognostic factor in colorectal cancer patients. Following in vitro studies revealed that HCT8 and HT29 cells transfected with p62-specific siRNA showed significantly decreased cell proliferation activity, whereas COLO320 and SW480 cells transfected with p62 expression plasmid showed significantly increased cell proliferation activity. The p62-mediated cell proliferation was not associated with the autophagy activity. These findings suggest that p62 promotes the cell proliferation mainly as a scaffold protein, and that the p62 status is a potent prognostic factor in colorectal carcinoma patients.

摘要

p62/自噬体相关蛋白 1(p62)是一种具有多种结构域的蛋白,作为选择性自噬中泛素化靶标的受体发挥作用,并作为各种信号级联反应中的支架。已有报道称,p62 在几种人类恶性肿瘤中上调,但在结直肠癌中,p62 的生物学功能和意义仍知之甚少。我们用免疫组化的方法对 118 例结直肠腺癌和 28 例结直肠腺瘤病例进行了 p62 评估。我们在体外研究中使用了四种结肠癌细胞(HCT8、HT29、COLO320 和 SW480)。p62 免疫反应性在 11%的结直肠腺瘤病例和 31%的腺癌病例中被检测到,而在正常上皮中则几乎检测不到。免疫组化 p62 状态与同步肝转移显著相关,在结直肠癌患者中是独立的不良预后因素。后续的体外研究表明,用 p62 特异性 siRNA 转染的 HCT8 和 HT29 细胞的增殖活性明显下降,而用 p62 表达质粒转染的 COLO320 和 SW480 细胞的增殖活性明显增强。p62 介导的细胞增殖与自噬活性无关。这些发现表明,p62 主要作为支架蛋白促进细胞增殖,p62 状态是结直肠癌患者强有力的预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48d/5463080/a2a157422aa9/CAM4-6-1264-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验